Research involving mice and samples from patients with multiple sclerosis reveals how anti-CD20 antibodies such as ocrelizumab protect neurons in gray matter, and ties the treatment’s effects to elevated levels of BAFF.
Research involving mice and samples from patients with multiple sclerosis reveals how anti-CD20 antibodies such as ocrelizumab protect neurons in gray matter, and ties the treatment’s effects to elevated levels of BAFF.
Comments are closed.